FY2022 Earnings Forecast for Orchard Therapeutics plc Issued By Cantor Fitzgerald (NASDAQ:ORTX)

Orchard Therapeutics plc (NASDAQ:ORTXGet Rating) – Stock analysts at Cantor Fitzgerald decreased their FY2022 earnings per share estimates for Orchard Therapeutics in a note issued to investors on Tuesday, November 15th. Cantor Fitzgerald analyst P. Stavropoulos now expects that the company will earn ($1.24) per share for the year, down from their previous estimate of ($1.04). Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Orchard Therapeutics’ current full-year earnings is ($1.14) per share. Cantor Fitzgerald also issued estimates for Orchard Therapeutics’ FY2023 earnings at ($0.52) EPS.

Orchard Therapeutics Price Performance

Orchard Therapeutics stock opened at $0.44 on Thursday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.24 and a current ratio of 4.24. The firm has a market capitalization of $55.92 million, a price-to-earnings ratio of -0.31 and a beta of 0.67. Orchard Therapeutics has a fifty-two week low of $0.41 and a fifty-two week high of $1.56. The stock’s fifty day moving average is $0.47 and its two-hundred day moving average is $0.52.

Institutional Trading of Orchard Therapeutics

Several large investors have recently bought and sold shares of ORTX. Bank of America Corp DE grew its holdings in Orchard Therapeutics by 130.8% in the first quarter. Bank of America Corp DE now owns 95,749 shares of the company’s stock valued at $68,000 after purchasing an additional 54,270 shares during the last quarter. Forefront Analytics LLC grew its holdings in Orchard Therapeutics by 89.7% in the first quarter. Forefront Analytics LLC now owns 99,741 shares of the company’s stock valued at $72,000 after purchasing an additional 47,175 shares during the last quarter. Millennium Management LLC acquired a new stake in Orchard Therapeutics in the second quarter valued at $106,000. Strategic Wealth Advisors Group LLC acquired a new stake in shares of Orchard Therapeutics during the third quarter valued at $258,000. Finally, GSA Capital Partners LLP boosted its stake in shares of Orchard Therapeutics by 10.5% during the first quarter. GSA Capital Partners LLP now owns 374,276 shares of the company’s stock valued at $266,000 after acquiring an additional 35,520 shares during the last quarter. Institutional investors and hedge funds own 40.96% of the company’s stock.

Orchard Therapeutics Company Profile

(Get Rating)

Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration.

See Also

Earnings History and Estimates for Orchard Therapeutics (NASDAQ:ORTX)

Receive News & Ratings for Orchard Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchard Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.